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1INTRODUCTION
Fever is always a mysterious and interesting puzzle to solve.
Despite interests in fever in competent host, most fever goes undiagnosed
(even without consulting a physician). Fortunately, fever in these patients
neither leaves trace nor any damage in the host.
Fever, in a compromised host, is always undisputedly significant as
their ability to mount inflammation/immunity is blunted and renal
transplant  recipient  patients  are  no  different.  Chronic  kidney  disease,  by
itself, is an immunocompromised state. These patients will be profoundly
immunosuppressed with drugs. Unlike others, fever in compromised host
is a medical emergency.
A prevalence of different etiology manifesting as fever is of utmost
importance, as it gives you the most common causes in our locality,
which might or might not be the same as that of a western literature/ a
study  done  elsewhere  in  the  country.  It  is  very  likely  that  there  will  be
difference in the fever pattern between different study population21
2It  helps us to get  early diagnosis,  knowing the disease pattern and
to start empirical drugs against the disease that is prevalent, which saves
time, money and more importantly “the precious life” of renal transplant
recipient patients, who mean even more to his family, after transplant.
Such is the impact.
3REVIEW OF LITERATURE
INTRODUCTION
Fever is an interesting companion of mankind from age old times.
Whether it is a friend or foe, is always an interesting question. It is
actually defined as an elevation in core body temperature above the daily
range for an individual. It is essential to describe a normal body
temperature.
NORMAL BODY TEMPERATURE
It varies throughout the course of the day with maximum normal
oral temperature at 6 AM is 37.2 ºC (98.9 ºF) and the maximum level at 4
PM is 37.7 ºC (99.9 ºF), both values defining the 99th percentile for
healthy subjects. It is controlled in anterior hypothalamus with
predominant site of production being muscle and liver, whereas
predominant site of dissipation is skin and lungs. Unfortunately due to
extremes of temperature, it is often not possible to maintain temperature
homeostasis with the help of dress and shelter1.
4The maximum normal oral temperature at 6 AM is 37.2 ºC (98.9
ºF) and the maximum level at 4 PM is 37.7 ºC (99.9 ºF) both values
defining the 99th percentile for healthy subjects. So a morning reading of
>37.2 ºC (98.9 ºF) or an afternoon temperature of >37.7 ºC (99.9 ºF)
would be considered a fever. Rectal temperature is0.6 ºC (1.0 ºF) higher
than oral readings. Oral readings are low probably because of mouth
breathing, whereas lower esophageal temperature reflects the core body
temperature and tympanic membrane temperature is close to it.
Normal  daily  variation  in  temperature  is  usually  between  0.5  –  1
degree Celsius. Range changes in pathological states.
Menstruation, ovulation, pregnancy, postprandial states can have
variation, contrary to routine rule. Children have a fixed daily variation,
whereas elderly weakly mount fever2.
5FEVER, HYPERTHERMIA, AND HYPERPYREXIA
Fever, hyperthermia, and hyperpyrexia are not synonymous terms.
Fever:
Fever thermostat is located in hypothalamus, which decides the
body temperature. An upward shift in the set point happens in fever,
mediated by PGE2.  Once the hypothalamic set-point is raised, this
activates neurons in the vasomotor center to commence vasoconstriction
and increase heat production in the periphery.
Heat conservation by vasoconstriction will raise core body
temperature 1ºC. Non shivering thermo genesis due to uncoupling of
oxidative phosphorylation takes place in muscle and adipose tissue.
Heat conservation and thermogenesis account for the major source
of heat generation, associated with a marginal heat production in liver.
Shivering of muscle is usually not needed unless there is a rapid rise in
set point. Human lifestyle changes accounts for remaining need.
When the set point is reset, opposite happens, resulting in
vasodilatation and sweating.
6Hyperthermia:
In contrast to fever, thermoregulatory set point remains at
normothermic levels and temperature increases and overwhelms the
ability to lose heat, resulting in alarmingly high body temperature
Hyperpyrexia:
Hyperpyrexia is alarmingly high temperature of >41.5 ºC, which is
observed usually in central nervous system hemorrhages and infections.
A pyrogen is any substance that can trigger fever and it can be
either exogenous or endogenous. Exogenous pyrogens are endotoxins of
gram negative infections and exotoxins and enterotoxins of gram positive
infections. Endotoxins, besides fever, are responsible for various other
pathogenetic process3. Endotoxins are toll-like receptor (TLR) ligands,
that activates macrophage, to generate cytokines resulting in fever4
The toxic shock syndrome toxin (TSST-1) of Staphylococcus
aureus isolated and other enterotoxins from S. aureus and exotoxins from
group A streptococcus act both as direct toxins and serve as
"superantigens" 5,6. Superantigen interacts with major histocompatibility
complex (MHC) II and a number of T cell subsets7,8 to release pyrogenic
cytokines
7Pyrogenic cytokines
Pyrogenic cytokines are proteins that regulate various components
of  immune  system.   Few  important  ones  are  namely  IL-1,  IL-6,  tumor
necrosis factor (TNF) and Ciliary Neurotrophic Factor (CNTF),
Interferon (IFN)-?. Others likely exist.
Inflammation, trauma or immune complex can also induce these proteins.
ELEVATION OF THE HYPOTHALAMIC SET-POINT BY
CYTOKINES
FIGURE 1: PATHWAYS OF FEVER PRODUCTION
8Cytokines stimulate PGE2 both centrally and peripherally. Central
production is responsible for fever, whereas the peripheral production is
responsible for myalgia, arthralgia and other prodromes.  PGE2 stimulate
receptors on glial cells to activate CAMP, which resets set point to a
higher level10.
It is very evident that anti cytokine therapy can mask fever. Despite
therapy, fever can manifest due to blocking of selective cytokines, while
the other cytokines express. It can also manifest if production
overwhelms therapy. Alternatively, microbial products can directly
stimulate PGE2 in brain.
Patient, whose cytokines are inhibited by either congenital or
acquired causes, can manifest fever, but the incidence and intensity is
grossly low in comparison with a normal host.
FEVER IN COMPROMISED HOST
An immunocompromised host behave in a totally different way
when compared to normal person in immune response, and in mounting
immunity against infections10.
9FEVER, IMMUNOSUPPRESSION, AND INFECTION
Fever may be the only manifestation of life threatening infection in
the compromised patient. No single pattern or degree of fever is
diagnostic of an infectious or a non-infectious cause11. It can be muted in
patients with an immunocompromised state, be it congenital or acquired12
Decision of immediate evaluation and prompt empirical treatment
is  of  utmost  importance  in  compromised  host13, 14.  Few  of  those  life
threatening conditions are profound neutropenia and splenectomy. It also
depends on the etiology of neutropenia, duration and associated defences
of the host.
Etiology of neutropenia is very important. Patients who develop
neutropenia after viral infection do much better than immunosuppresed
patient with drugs after post-transplant or cancer chemotherapy. If you
look deeply the latter group also have mucosal breech due to inhibition of
rapidly proliferating cells, in gastro intestinal tract, respiratory tract and
urinary tract15.
Functionally asplenic or who have had a splenectomy, have
increased vulnerability fulminant infections with encapsulated organisms.
Most common infection includes Streptococcus pneumoniae, Neisseria
10
meningitidis, and Haemophilus influenza. Incidence is very high if they
are not immunized or in patients with emergency splenectomy. These
subsets of patients are highly fragile because they go in for multi organ
dysfunction and cardiovascular collapse very early in clinical course.
Besides neutropenia, life threatening infections are common in
individuals with severe derangement of humoral and cell mediated
immunity.  Patients  with  CD4  cell  counts  less  than  200  per  cubic
millimeter in children more than six years of age and adults are at risk for
life-threatening infections with Pneumocystis carinii and other
opportunistic infections, which will have a fulminant course, if not treated
early. Except tuberculosis, opportunistic infection is uncommon if CD4
count is less than 200.  Incidence of Mycobacterium avium-intracellulare
is unlikely with CD4 count less than 50.
Patients, who are  on immunosuppressive therapy after organ
transplantation or  for  an autoimmune disease,  are at  a  high risk of  being
infected with a gram positive or gram negative organisms during early
days. Subsequently they succumb to organisms that are cleared by cell
mediated immunity (Toxoplasma, Pneumocystis and so on)
11
INFECTIONS IN IMMUNOCOMPROMISED – A WIDE
SPECTRUM
There is an endless list of infection in the immunocompromised
host.  It  is  possible  that  every  organism  existing  can  become  invasive  in
these patients. No algorithm is appropriate in these individuals, but the
organism can be predicted based on the degree, duration of
immunosuppresion and the common organisms that is prevalent in the
locality.
A change in trend has been observed over the past few decades in a
variety of patients with different etiology.
One of the most important threats in a compromised host comes from
bacteriae.
In neutropenics, in the developing nation, the most common
isolates are gram negative organisms, namely Klebsiella, Pseudomonas, E
coli.
Despite their abundance, infection with gram positive organism, is
usually not life threatening. Patients with gram negative bugs can pursue
a fulminant course, if not treated early and appropriately.
12
Individuals who underwent splenectomy or individuals harbouring
HIV infection are prone to develop infections by capsulated organisms
and gram negative bacteriae.
Patients with neutropenia due to cytotoxic therapy are susceptible
to infections with viruses (herpes viruses and respiratory viruses), fungi
and parasites.
For practical purposes, neutropenics are divided into low- and
high-risk groups based on the projected duration of neutropenia. Low risk
groups are those with projected duration of neutropenia less than 10 days
and they fair well to come out of the crisis. High risk patients with
duration lasting more than 10 days are vulnerable to acute bacterial
infections, fungi, parasites and viruses. In addition, they are prone for
recurrent infections, relapse, polymicrobial infections.  Obviously, the
latter situation poses a diagnostic as well as a therapeutic challenge.
Patients with hematological transplants, succumb to neutropenia
early. Once reconstitution occurs, they are prone to infection with
capsulated organisms. Those with solid organ transplantation, it depends
on the type and nature and duration since transplant.
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Gram negative infection and sepsis are common in renal transplant
patients. Enterally derived pathogens and ascending cholangitis are
common in liver transplant patients. Mediastinitis and pneumonia are
more common in heart or lung transplantation.
Similar to bacteriae, viral infections are also predisposed by many
factors. One such example is the timing of infection in herpes virus in
marrow or solid organ transplantation, where different species of herpes
virus present in different months.
Epstein Barr virus and its clinical features vary widely from a
benign to completely malignant disease.
In solid organ transplantation with central nervous involvement,
Listeria and Cryptococcus should always be kept in mind.
Other possible infections in HIV positive patients include a variety
of agents depending on the CD4 count. Pneumocystis infection with CD4
counts less than 200.  Mycobacterium avium-intracellulare with CD4
count less than 50 and mycobacterium tuberculosis can infect in a variety
of CD4 count.
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RENAL TRANSPLANT
Renal transplantation is the best available treatment at present for
patients with chronic kidney disease. Around the globe the procedure has
become rampant. When azathioprine and prednisone initially were used
as immunosuppressive drugs in the 1960s, the results with properly
matched familial donors were superior to those with organs from
deceased donors; 75–90% compared with 50–60% graft survival rates at
1 year. Well today the one year survival rate for deceased donor is 89%
and for living donor is 95%. Today the average survival time for a live
matched donor is 20 years and for deceased donor is 14 years
Post-transplant mortality rate is highest in the first year and is age
dependent, which is directly proportional to age. Non-compliance of drug
may drastically worsen renal function through rejection. Most grafts,
however, succumb at varying rates to a chronic process consisting of
interstitial fibrosis, tubular atrophy, vasculopathy, and glomerulopathy,
the pathogenesis of which is incompletely understood. There are 2,00,000
functioning kidneys after transplant around the world as it totally changes
the  lifestyle  of  the  patient  when  compared  to  other  modes  of  renal
replacement therapy.
15
Expanded Criteria Donor (ECD)
1. Deceased donor >60 years
2. Deceased donor >50 years and hypertension and creatinine>1.5 g/dL
3. Deceased donor >50 years and hypertension and death caused by
cerebrovascular accident (CVA)
4.  Deceased donor >50 years and death caused by CVA and
creatinine>1.5 mg/Dl
Donation after Cardiac Death (DCD)
1. Brought in dead
2. Unsuccessful resuscitation
3. Awaiting cardiac arrest
4. Cardiac arrest after brainstem death
5. Cardiac arrest in a hospital patient
TABLE 1: EXPANDED CRITERIA FOR DONOR AND
DONATION AFTER CARDIAC DEATH
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Recipient Selection
Very few absolute contraindications to renal transplantation exist.
The procedure is relatively non-invasive, and the organ is placed in the
inguinal fossa outside the peritoneum. Recipients can be discharged
within a week of transplant, provided there are no perioperative
complications.
Patient receiving transplant invariably have a morbidity and
mortality benefit, as compared to those on long term dialysis. Elderly and
older patients, even if they have a higher mortality, do much better with
transplant than dialysis. This resulted in substantial demand to the
deceased kidneys as the need keeps on multiplying rapidly. This poses a
threat to the policy makers to use stringent guidelines for the recipients.
Recommendation is a minimum life expectancy should be more
than 5 years.
It applies to both deceased and living donor transplantation and this
is due to the high immediate transplant period complications, which is
very high when compared to those on dialysis. Risk benefit ratio has to be
thoroughly analysed. Patients should be thoroughly screened for HIV and
hepatitis before considering transplant. Most places consider this as near
17
absolute contraindication for transplant. But people do operate in few
centers, to find out the superiority of one over the other.
Immunological absolute contraindication includes the presence of
pre-existing antibody that is going to reject the kidneys immediately.
They are anti ABO antibody and anti HLA antibody against the organ.
All necessary steps to overcome such mismatch, should be done.
Donor Selections
Donors can be deceased or volunteer living donors. The living
donors are selected from the family to have more HLA match. Living
volunteer donors should have the same ABO blood group and should be
normal on physical examination. However we can transplant a kidney
from O blood group donor to a recipient of any blood group. Renal
arteriography should be done to find out stenosis, variations and other
abnormalities of the vessel, which can affect the procedure and can delay
the ischemic time. Donors are increasingly operated laprascopically these
days, which has reduced the hospital stay, scar, and nosocomial infection.
Deceased donors should be free of malignant neoplastic disease, hepatitis,
and HIV because of possible transmission to the recipient. Graft failure
increase when the donor is aged or has a pre-existing renal dysfunction or
prolonged period of ischemia and storage.
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Tissue Typing and Clinical Immunogenetics:
HLA major histocompatability matching is an extremely important
criterion for renal allograft, donor selection. Each individual has a single
region that is located in the sixth chromosome which encodes major
transplantation antigen.
HLA antigens DNA genomic sequences are increasingly being
used these days. Blood group antigens, endothelial antigens and minor
antigens play an important role. Few of the HLA identical grafts are also
rejected. All these tell us they are sensitized to minor antigens previously.
Well these antigens are relatively suppressible by drugs provided no
priming has occurred.
Immunosuppression:
The idea of increasing life span by organ transplantation had long
been a dream for the medical fraternity. Early efforts at transplantation
were unsuccessful due to inadequacies in surgical technique and
insufficient knowledge of the immune system.
Many surgical procedures failed during the early days. This dated
back to 1933.Total body irradiation was used as a tool to
immunosuppress the patient in the early days, when the concept of
19
rejection was blossoming. Next came the era of steroids alone, which was
not successful.
Subsequently, with the development of 6-mercaptopurine,
azathioprine in the early 1960s, pharmacological suppression stole the
show and has become the standard of care.
The first successful series of transplant were between 1962 and
1964. Sooner, the combination of azathioprine and steroids came to
practice and was the widely used combination and became a routine pillar
of immunosuppression.
As  our  knowledge  of  the  immune  system  evolved  with  time,
therapy targeted to specific immune-regulatory sites unfolded and raised
new horizons in the treatment of transplant medicine. The first polyclonal
antilymphocyte globulin was used in 1967 and it seeded the hopes and
paved the way for other drugs.
Cyclosporine was introduced as a calcineurin inhibitor in 1980 and
was combined with steroids, azathioprine, which created wonders in graft
survival.
Both tacrolimus and mycophenolate mofetil were introduced in
1994.  Tacrolimus has slowly replaced cyclosporine.  MMF has virtually
20
replaced azathioprine universally.  To expand the armamentarium further,
sirolimus, a macrolide antibiotic, was introduced recently and the exact
role of which is yet to be defined.
Then came the era when people started thinking about the side
effects of the drugs which might affect the patients adversely and in turn
can have a worse outcome in the graft.
21
BRIEF REVIEW OF THE INDIVIDUAL DRUGS:
Azathioprine:
It  is  a  derivative  of  6-mercaptopurine.  It  is  used  as  an
antimetabolite to decrease DNA and RNA synthesis and it is used as a
drug for maintenance immunosuppression.
Toxicity:
? Marrow bi to tri lineage suppression
? Gastrointestinal symptoms
? Variable liver involvement
? Cholestasis
? Hair loss
Watchful monitoring of liver enzymes, pancreatic enzymes and
complete blood count has to be done periodically.
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Corticosteroids:
Corticosteroids inhibit production of IL –1 and IL-6 by
macrophages. It also inhibits all stages of T-cell activation. It can be used
as an induction agent, maintenance agent, and also useful in the treatment
of acute rejection.
Toxicity:
? Cushings  syndrome
? Osteopenia and easily prone for fracture
? Cataracts
? Impaired glucose intolerance
? Recurrent  infections
? Dyslipidemia
? Poor wound healing
? Growth retardation
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Cyclosporine:
It prevents the production of IL-2 and thus preventing the
activation of helper T cells. It binds to cyclophilin binding protein and is
used for induction as well as maintenance.
Toxicity:
? Nephrotoxicity
? Electrolyte imbalance commonly Hyperkalemia, hypomagnesemia
? Gastro intestinal intolerance
? Hypertrichosis, hirsuitism
? Gingival hyperplasia
? Dyslipidemia, glucose intolerance
? More prone for infection, malignancy, and hyperuricemia.
Switching from cyclosporine to tacrolimus alleviates side effects
like hirsuitism.
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Tacrolimus:
It is a macrolide antibiotic that inhibits the production of IL-2 by
binding to tacrolimus binding protein. It is used as a maintenance therapy
or it can be used in patients with refractory rejection.
Adverse effects
? Nephrotoxicity
? Neurotoxicity
? Glucose intolerance
? QT prolongation
Cosmetically, it is much superior to cyclosporine. It can cause
reversible alopecia that can recover with lowering or stoppage of drugs.
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Mycophenolate mofetil:
It is an inosine monophosphate dehydrogenase inhibitor and hence
selectively impairs proliferation of B and T cells, without affecting the
other rapidly proliferating cells due to rescue through salvage pathway.  It
is used for maintenance and chronic rejection. Newer enteric coated
tablets have come to the market with decreased side effects.
Adverse effects:
? Gastro intestinal intolerance
? Pancytopenia
Hematological toxicity is worsened if concurrently administered with
azathioprine.
Levels of the drug will be increased if concurrently administered with
tacrolimus.
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Sirolimus:
It acts by binding to FK binding protein, and it acts through
mTOR(mammalian target of rapamycin).  It inhibits cell proliferation by
inhibiting G1 to S phase of cell cycle proliferation. This agent is used for
maintenance immunosuppression and chronic rejection.
Adverse effects
? Electrolyte imbalance commonly potassium and magnesium
disturbances
? Dyslipidemia
? Bicytopenia and occasionally tri lineage suppression
? Impaired wound healing
? Seroma
It has a relatively long half -life and hence it can have interactions
with the other drugs. Despite that, it can be used with other drugs.
27
BIOLOGICAL AGENTS:
Polyclonal Antibodies:
Polyclonal antibodies are produced by injecting human lymphocyte
into other species. It elicits an antibody response to human antibody.
These antibodies are isolated and harvested. These antibodies kill the host
lymphocytes by complement mediated lysis and by the activation of
reticulo endothelial system.
Adverse effects:
? Fever, chills
? Pancytopenia
? Hemolyticanemia
? Respiratory distress
? Serum sickness and anaphylaxis
A major drawback is its association with non hodgkins lymphoma,
when administered in high doses. [18]
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MONOCLONAL ANTIBODIES:
Muromonab-CD3:
Muromonab-CD3 (OKT3) is a monoclonal antibody of
immunoglobulin to the CD3 portion of the T-cell receptor and hence
blocks the cell lineage activation. It is used for acute rejection and
resistant cases.
Adverse effects
? Cytokine release syndrome
? Pulmonary edema
Monoclonal Anti-CD25 antibody:
Basiliximab and daclizumab are humanized monoclonal antibodies,
which targets against IL-2 receptor. Both of them are used as induction
agents, and are very similar in most aspects.
Adverse effects
? Hypersensitvity effects
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Monoclonal Anti-CD20 antibody:
Rituximab is a monoclonal antibody that is directed against CD 20
of B cells. Its use is currently being studied in treatment of some forms of
antibody-mediated rejection. Another area of possible utility is in the
hypersensitized patient awaiting transplant. Monoclonal antibodies are
relatively much expensive drugs when compared to their counterparts.
INFECTIONS IN POST RENAL TRANSPLANT:
Risk of infection in the post-transplant patient is determined by the
extent of epidemiologic exposures and immune defects. Infection can be
acquired from the organ, hospital or from the community. Sometimes the
infection may get reactivated in the recipient, which was latent prior to
immunosuppression.  When there is a major infection the risk of mortality
doubles and has huge impact in patients and graft survival.20
The  precise  timing  of  infection  is  determined  by  the  interplay  of
host, environmental factors and the duration and degree of
immunosuppression.
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Timeline classification of renal transplant infection is broadly
divided into three categories
1. Less than one month of transplant ( perioperative  and in-hospital
infection )
2. Within one to six months of transplant
3. More than six months of transplant(some classify > one year )
INFECTION LESS THAN ONE MONTH:
In the first category which is basically early transplant infection,
the source of infection either pre-exists in the host or acquired during the
perioperative hospital stay.  One common mode is the recipient is having
a nidus of infection commonly a preoperative pneumonia or indwelling
device  related infection or infection of the fistula .
Most of the infection during this period is hospital acquired and
can be either due to infections in the donor or transmitted through graft
during different time.  A notable difference is such infections through the
graft need not follow the routine time table and can be early as well.
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The most common infection at this point in time is similar to a
normal person and is usually procedure related. Sterile techniques and
meticulous hands yield excellent results.  The routine nosocomial
pathogens and sites are implicated in these patients. A good post-
operative care invariably reduces the chances of infection widely. Apart
from  routine  prophylaxis,  an  additional  MRSA  cover  is  all  that  is
required.
A striking fact is opportunistic infection is uncommon in the first
one month despite a heavy immune suppression in this period.
Bacterial  and/or  fungal  organisms  are  transmitted  by  a
contaminated allograft although donors are usually carefully screened for
presence of contaminating organisms.
The categorization of post-transplant infections may be used in a
variety of ways:
1. To shortlist infections in that stipulated period
2. As a clue to the presence of an excessive environmental hazard
for the individual, either within the hospital or in the
community, and
3. As a clue to the empirical treatment.
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An infection that does not follow the timetable tells either the
excessive vulnerability of the individual or excessive prevalence of
infection in that particular community.
Prophylaxis of infection is usually based on the time table or the
timeline of infection.
LIST OF INFECTION (2-6 MONTHS) AFTER
TRANSPLANTATION:
Opportunistic infections:
o Toxoplasma gondii
o Pneumocystis carnii
Other infections:
o Strongyloides and other parasites species
o Fungi
o Tuberculosis
Viral infections(or its reactivation):
o Cytomegalovirus, Herpes group of virus, hepatitis B virus,
hepatitis C virus.
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LIST OF INFECTION AFTER SIX MONTHS OF
TRANSPLANTATION:
As the immunosuppression is reduced, the amount of infection falls
gradually in this sub group.
Infections in this population is similar to those in the community
o Common respiratory tract infections
o Common viral infections
o Urinary tract infections
Many viral infections not only affect the organs and grafts, but it
also has some immune modulating property which predisposes to various
other infections say aspergillus,Pneumocystis.25,26,27,28
Most patients who died in the hospital with significant liver
pathological states had hepatotropic viral infections22. Preemptive renal
transplantation, when possible, has been shown to reduce viral infections
and improve survival23.
In western India, malaria continues to be an important differential
diagnosis, not only for the febrile syndrome but also for a clinical picture
of rejection24.
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FIGURE 2: TIMETABLE OF INFECTIONS IN RENAL
TRANSPLANT RECIPIENTS
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Immediate post-transplant period (30days)
o Opportunistic infections are uncommon
o It takes almost a month time to effectively suppress the T cells
and large dose of corticosteroid is an exception
o Vulnerable to hospital infection or transmitted through the graft.
Intermediate period (1-6months)
o Rejection episodes and infections through viruses are the major
concern in this timeline.
o Adherence to time table and proper anti-infective prophylaxis
effectively can avoid morbidity and mortality.
o Fungi,and parasites can surface
o Rarely polyoma virus (BK and JC) and more commonly HCV.
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Late post-transplant period (>6months)
o Immunosuppression is slowly tapered and risk is on the decreasing
trend.
o However with each acute rejection, timeline is reset and starts over
again.
o Chronic viral infections can cause allograft injury and few of the
undesirable complication listed below:
o HCV leads to cirrhosis
o BOOP in lungs
o CMV leads to coronary vasculopathy
o PTLD
o Skin/anogenital cancers
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NON INFECTIVE CAUSES OF FEVER:
GRAFT REJECTION:
It is immune mediated and can potentially present with fever.
Identifying is of utmost importance as treatment is increasing
immunosuppression contrary to infection where the dose of
immunosuppressants needs to be reduced.
MALIGNANCY:
The most common malignancies to present with FUO are:
? Lymphoma
? Leukemia
? Renal cell carcinoma
? Hepatocellular carcinoma
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DRUGS:
It is one of the common findings but often under diagnosed entity.
It usually simulates an allergic or an idiosyncratic reaction. It rarely can
affect the thermoregulation also.
Approximately 25% of the patients have rash and eosinophilia and
hence their absence should not rule out the diagnosis19.
The diagnosis of drug fever is made by a therapeutic trial of
stopping the suspected drug (with occasional rechallenge). Most patients
will defervesce within 72 hours after substituting drugs, although some
may  not  recover  for  weeks.  Drugs  of  the  same  class  should  not  be
reintroduced in a therapeutic trial.
Connective tissue, autoimmune, hypersensitivity diseases are less
common in immunosuppressed patients
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STUDY PROTOCOL
AIMS AND OBJECTIVES
1. To identify the etiology of fever in renal transplant recipient
patients, to establish the existing pattern in our locality
2.  To identify associations between donor, recipient factors and the
etiology, if any
MATERIALS AND METHODS
Place of study: Department of Nephrology, Transplant Recipient
Ward, Stanley Medical College and Hospital.
Duration: Mar 2012 to Nov 2012
Study Design: Descriptive prospective observational Study
Patient selection:
1.  Any  renal  transplant  recipient,  who  presents  to  The  Dept.  of
Nephrology, with fever at any point in time.
Exclusion criteria:
1. Patients who are not willing to get investigated in complete.
2. Patients absconded before full evaluation
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METHODOLOGY:
Transplant patients who developed fever any time after surgery
will be taken into the study. Invariably, all immediate post-transplant
patients will be admitted in the transplant ICU till they become stable and
will be shifted to transplant recipient ward. All patients who present to us
with fever in transplant OPD will be admitted to the ward and
investigated, immaterial of the duration and seriousness of the illness.
? All the patients were enquired about the history and examined
completely
? Initial investigations were towards the pertaining clinical clue
? If we do not have clinical clue, battery of tests were run keeping
the cost benefit analysis in mind and the common organisms
encountered based on the past experience and prevalence of the
infection.
? Wherever possible culture and tissue demonstration is attempted.
? Patients were treated and followed up in the transplant OPD.
? Data through the above mentioned ways are collected and tabulated
and analysed for the site of infection, prevalence of organisms,
various interplay of host and environmental factors.
? A diligent attempt is made to find out non-infectious cause of
fever, if any.
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RESULTS
Number of fever cases in renal transplant recipients for the most
part of the year in 2012 are 45. There are approximately 180 cases of
transplant recipients, who are on follow up with us. This tells us the
substantial morbidity of fever in renal transplantation. Fever, by itself, is
an under expressed entity in these patients due to immunosuppression.
So, the underlying disease which has manifested as fever is represented
only like a tip of iceberg.
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AGE DISTRIBUTION:
It was predominantly the younger population that presented with
fever, because the number of recipients were more in the younger
population. The age cut off for dividing the population is 40. Thirty two
patients were younger than 40 and thirteen were over 40.
AGE DISTRIBUTION NO OF PERSONS PERCENTAGE
< 40 YRS 32 71.1%
> 40 YRS 13 28.9%
TABLE 2: AGE DISTRIBUTION
GRAPH 1: AGE DISTRIBUTION
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SEX DISTRIBUTION:
SEX NO OF PATIENTS PERCENTAGE
MALE 38 84%
FEMALE 7 16%
TABLE 3: SEX DISTRIBUTION
Out of the 45 cases admitted with fever, there were 38 males and 7
females. The sex ratio of transplant patients in general was very adverse
towards women. Interestingly, there were 9 deaths in the study and all of
them were males and 5 readmissions in study period and all of them were
males. There is not a single death/readmission in the female study
population.
GRAPH 2: SEX DISTRIBUTION
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Regarding the other parameters like pre-existing disease,
epidemiological exposure, all the cases neither had a pre-existing disease
nor an epidemiological exposure in the past.
NATIVE KIDNEY DISEASE DISTRIBUTION:
NATIVE KIDNEY DISEASE NO OF PATIENTS PERCENTAGE
NOT KNOWN 44 97.8%
KNOWN 1 2.2%
TABLE 4: NATIVE KIDNEY DISEASE
GRAPH 3: NATIVE KIDNEY DISEASE
Only 1 out of the 45 patients had a known native kidney disease prior to
transplant.  The patient had Anti GBM disease and that accounts for 2%
in the study.
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NATURE OF DONOR:
NATURE OF DONOR NO OF PATIENTS PERCENTAGE
LIVE RELATED 33 73.3%
CADAVER 12 26.7%
TABLE 5: NATURE OF DONOR
GRAPH 4: NATURE OF DONOR
In  the  study,  we  had  33  recipients  from live  related  donor  and  12
from cadaveric donors. Surprisingly, 8 deaths were recipients from live
related  donors  out  of  9  deaths.  We  had  5  readmissions,  out  of  which  3
were from live related renal transplants and 2 were from cadaveric renal
transplant.
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27%
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TREATMENT FOR REJECTION:
Among the fever patients, seven were treated for acute rejection at
least once during the post-transplant period.
A table that classifies the involvement of organ system is represented
below:
LOCATION
NO OF PERSONS
TREATED FOR
REJECTION EARLIER
PERCENTAGE
RESPIRATORY
TRACT 4 57.1%
GASTRO
INTESTINAL
TRACT
1 14.3%
HCV 1 14.3%
BONE MARROW 1 14.3%
TABLE 6: TREATMENT FOR REJECTION
Majority of the patients who had fever and who had treatment for
rejection had respiratory tract infection. Gastrointestinal manifestation,
bone marrow involvement and viremia were noticed in three patients (one
in each).
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GRAPH 5: DISTRIBUTION OF LOCATION OF INFECTION
AMONG PATIENTS TREATED FOR REJECTION
One patient succumbed to death out of the four of respiratory tract
infection.
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LEVEL OF TACROLIMUS:
All  the  patients  were  under  triple  immune  suppression  with
prednisolone, tacrolimus and mycophenolate mofetil. We routinely check
tacrolimus levels for any patient with fever and / or unexplained decrease
in graft function. We could not check mycophenolate mofetil levels due
to financial constraints.
In this study 16, patients had high tacrolimus levels, which is just
over one third of the patients. Rest had their levels in the therapeutic
range.
LOCATION OF INFECTION NO OF PATIENTS PERCENTAGE
RESPIRATORY TRACT 9 56.25%
ABDOMEN AND
GASTROINTESTINAL 4 25%
SEPSIS WITH NO OTHER
FOCUS 1 6.25%
TUBERCULOSIS OF BONE
MARROW 1 6.25%
UNDIAGNOSED 1 6.25%
TABLE 7: FOCUS OF INFECTION AMONG THOSE WITH HIGH
TACROLIMUS LEVELS
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Nine out of sixteen patients with high tacrolimus levels had a
respiratory focus of infection. Four had their source in the abdomen and
the rest had one case each.
GRAPH 6: DISTRIBUTION OF DEATHS AMONG PATIENTS
WITH HIGH TACROLIMUS LEVELS
Eighty percent (4) of the patients who died along with high
tacrolimus levels were due to respiratory tract infections. The remaining
20% (1) of the patients died of gastrointestinal involvement.
There was no difference among the patients in vaccination and
Pneumocystis carnii prophylaxis, as all of them were adequately
vaccinated and were adherent to pneumocystis prophylaxis.
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PATIENTS WITH HIGH TACROLIMUS LEVELS
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NODAT (New onset diabetes after transplant):
PRESENCE OF NODAT NO OF PATIENTS PERCENTAGE
YES 7 15.6%
NO 38 84.4%
TABLE 8: PRESENCE OF NODAT
GRAPH 7: PRESENCE OF NODAT
We observed, 7 patients had NODAT out of the 45. One patient
who died due to the disease had a co-existing NODAT.
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CLINICAL CLUES:
Transplanted patients are tightly immunosuppressed to avoid
rejection. In the process, clinical clues become thinner and thinner. It is
good to look back and find out the spectrum of signs, symptoms and the
system involved. Indeed, they are overwhelming signs despite
immunosuppression.
SYSTEM WISE MANIFESTATION NO OF PERSONS
GIT 8
RESOIRATORY 7
SKIN 5
ORTHOPAEDIC 1
ENT 1
CNS 1
NO CLUES 22
TABLE 9: CLINICAL CLUES
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GRAPH 8: CLINICAL CLUES
A striking fact in the chart is 49% of the patients did not have any
clinical clue to pinpoint investigations. Gastrointestinal tract, respiratory
tract and skin manifestations are the next common systems involved in
descending order.
We had one case each with clinical clue in ENT,
ORTHOPAEDICS, CNS.
Retrospectively analysing all these patients, without any other clue
after investigation, revealed etiologies in most of them.
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INVESTIGATIVE
DIAGNOSIS IN
CLINICALLY MUTE
PATIENTS OTHER THAN
FEVER
NO OF
PERSONS PERCENTAGE
UNDIAGNOSED 6 27.3%
PNEUMONIA 5 22.7%
UTI 4 18.3%
MALARIA 2 9.1%
HCV 2 9.1%
SEPTICEMIA WITHOUT
FOCUS 1 4.5%
PP 65 1 4.5%
TB GRANULOMA IN BONE
MARROW 1 4.5%
TABLE 10: INVESTIGATIVE DIAGNOSIS IN CLINICALLY
MUTE PATIENTS
Still in patients who did not have any other clue, a majority of the
patients remained undiagnosed, even after investigating.
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GRAPH 9: INVESTIGATIVE DIAGNOSIS IN CLINICALLY
MUTE PATIENTS
We can see the majority of the patients, with no other clue were
undiagnosed even after investigations. Next common diagnosis is
pneumonia, followed by urinary tract infections. Malaria, HCV, sepsis,
PP65, Granuloma are other investigations contributing to the list in
descending order.
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HIERACHY OF USEFUL INVESTIGATIONS IN PATIENTS
WITH NO OTHER CLINICAL CLUES:
1. CT CHEST
2. URINE CULTURE AND SENSITIVITY
3. QUANTITATIVE BUFFY COAT
4. HCV RNA
5. BLOOD CULTURE AND SENSITIVITY
6. PP 65
7. BONE MARROW ANALYSIS
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ANALYSIS OF INVESTIGATIONS:
Investigations are very important in evaluating any patient. There
are situations in which clinical scenario can be masquerading or muted.
One such situation is immunosuppression.
The number of investigations and the number of patients don’t tally
here as one patient requires more than one investigation to arrive or
conclude at a diagnosis.
Hence it is of utmost importance and worthwhile to rewind and
have a good look at the investigations that helped us.
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INVESTIGATIONS NO OF CASES PERCENTAGE
CULTURE AND
SENSITIVITY 17 31.4%
CT CHEST 10 18.4%
TZANCK SMEAR 4 7.4%
HCV RNA 4 7.4%
BIOPSY 3 5.6%
CT ABDOMEN 2 3.7%
PCR 1 1.9%
PP65 1 1.9%
CSF ANALYSIS 1 1.9%
STOOL ROUTINE 1 1.9%
URINE DECOY
CELLS 1 1.9%
NONE 9 16.6%
TABLE 11: ANALYSIS OF INVESTIGATIONS
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GRAPH 10: ANALYSIS OF INVESTIGATIONS
It is striking that culture and sensitivity, is the predominant
yielding investigation in the study, which will be the same in any study in
which disease is predominantly caused by an infectious agent.
Next to culture, it was CT chest that gave clue to the disease in 10
individuals.  9 patients remained undiagnosed at the end of investigations.
Tzanck  smear,  HCV  RNA,  biopsy,  CT  abdomen,  PCR,  PP  65,csf
analysis, urine decoy cells, stool routine are the other investigations that
revealed clue to the underlying disease in descending order.
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Infections in renal transplant recipients are classically classified
essentially into 3 different categories.
1. Infection less than  1 month
2. Infection  between  1 -  6 months
3. Infection more than 6 months
This classification helped us understand how a renal transplant
recipient succumbing to infection is similar or different from a normal
human succumbing to infection. This was proposed by Rubin  et  al.
There are Indian data which had modified the time table as per prevalence
in our country.
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INFECTION LESS THAN 1 MONTH:
Infections less than 1 month are usually no different than any other
normal person. The predominant infections are post operative and
hospital acquired infections, in our study.
GRAPH 11: ETIOLOGY OF FEVER IN LESS THAN 1 MONTH
POST-TRANSPLANT
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INFECTIONS LESS
THAN 1 MONTH NO OF PERSONS PERCENTAGE
PNEUMONIA 2 50%
UTI 1 25%
RETROPERITONEAL
ABSCESS 1 25%
TABLE 12: ETIOLOGY OF FEVER INLESS THAN 1
MONTH POST-TRANSPLANT
Out of the 4 cases in the post-transplant period 2 are pneumonia, 1
urinary tract infection and 1 retro peritoneal abscess. All 4 cases are
either operative complication or hospital acquired infections.
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Analyses of the infective etiology are discussed below.
ORGANISM NO OF PERSON PERCENTAGE
PSEUDOMONAS 1 25%
KLEBSIELLA 1 25%
E COLI 1 25%
ENTEROBACTER 1 25%
TABLE 13: ANALYSIS OF INFECTIVE ETIOLOGY
GRAPH 12: ANALYSIS OF INFECTIVE ETIOLOGY
We had one case each of pseudomonas, Klebsiella, E coli, Enterobacter.
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INFECTIONS BETWEEN 1 – 6 MONTHS:
INFECTIOUS FOCI AND
LOCATION
NO OF
PERSONS PERCENTAGE
PNEUMONIA AND
LUNG ABSCESS 8 34.9%
SKIN;HERPES 2 8.7%
MALARIA 2 8.7%
WRIST;TUBERCULOSIS 1 4.3%
RETROPERITONEAL
ABSCESS 1 4.3%
GI TRACT ;
CRYPTO SPORIDIOSIS
1 4.3%
HCV 1 4.3%
POLYMICROBIAL
SEPSIS WITHOUT
FOCUS
1 4.3%
UNDIAGNOSED 6 26.2%
TABLE 14:  ETIOLOGY OF FEVER IN BETWEEN 1- 6
MONTH POST-TRANSPLANT
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DISTRIBUTION OF THE INFECTIOUS AGENT
INFECTIONS NO OFPERSONS PERCENTAGE
HERPES 2 8.8%
TUBBERCULOSIS 1 4.3%
PNEUMOCOCCUS 2 8.8%
MUCORMYCOSIS 3 13%
ASPERGILLUS 2 8.8%
POLYMICROBIAL 3 13%
PSEUDOMONAS 1 4.3%
CRYPTOSPORIDIOSIS 1 4.3%
HCV 1 4.3%
ENTEROBACTER 1 4.3%
UNDIAGNOSED 6 26.1%
TABLE15: INFECTIOUS AGENTS IN FEVER BETWEEN 1-
6 MONTH POST-TRANSPLANT
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GRAPH 13: INFECTIOUS AGENTS IN FEVER BETWEEN
1- 6 MONTH POST-TRANSPLANT
Almost  one  quarter  of  the  patients,  with  fever  between  1  –  6
months post-transplant did not have any identifiable agent.
Among  the  agents  that  were  identified,  the  most  common  agents
were Mucor and poly microbial infections. Both of them, contributing to
13% independently. The next common organisms are Herpes,
Pneumococcus and Aspergillus and each of them contributed to around
9%.Tuberculosis has been identified in 5% of the population and the rest
of the organism contributed to 4% each.
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INFECTIONS IN RECIPIENTS MORE THAN 6 MONTHS:
There were 19 patients in this group. List of systems involved and
organism involved are depicted below.
INFECTIONS (FOCUS) NO OF PERSONS
UTI 3
LIVER AND GI TRACT(HCV) 3
RESPIRATORY
TRACT(PNEUMONIA) 3
ENT 2
SKIN;HERPES 2
CNS 1
CMV VIREMIA 1
BONE
MARROW(TUBERCULOSIS) 1
UNDIAGNOSED 3
TABLE16: ETIOLOGY OF FEVER INMORE THAN
 6 MONTHS POST-TRANSPLANT
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A quick look into the infections those are responsible for fever
more than 6 months are projected below.
GRAPH 14: ETIOLOGY OF FEVER IN MORE THAN
 6 MONTHS POST-TRANSPLANT
There  are  3  splits  in  the  picture  sharing  15% each  contributing  to
the majority of the infections. They are HCV, Aspergillosis, and the
infections in the last split could not be cracked and hence remained
undiagnosed.
Herpes, polymicrobial infections and E coli are the other infections
that  contributed  to  10%  of  the  infections.  BK  virus,  CMV,  Klebsiella
contributed to 5% each.
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MIXED INFECTONS:
Among the patients infected, there are 5 polymicrobial infections.
There were no mixed infections in less than one month group. There were
three polymicrobial infections in 1 – 6 months group and 2 in more than 6
months group.
MONTHS
AFTER
TRANSPLANT
LESS THAN
ONE
BETWEEN
ONE TO SIX
MORE
THAN SIX
NO OF CASES NIL 3 2
PERCENTAGE 0% 60% 40%
TABLE 17: DISTRIBUTION OF MIXED INFECTIONS WITH
RESPECT TO POST-TRANSPLANT DURATION
The organisms that are detected in polymicrobial infections are
Pseudomonas, Klebsiella, Aspergillus and E.coli.
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It is also prudent to discuss the site of polymicrobial infections.
GRAPH 15: SITEWISE DISTRIBUTION OF POLYMICROBIAL
INFECTIONS
Distribution of polymicrobial infections based on location revealed
lung and urinary tract infections in 80% of the patients (sharing 40%
each). One individual had polymicrobial sepsis identified in blood
culture, with no other recognizable primary focus of infections.
A very important observation is all polymicrobial infections
between 1-6 months succumbed to infection (accounts for 60%
polymicrobial infections).
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READMISSIONS:
? Out of 45, 5 had readmissions.
? All 5 of them are males.
? Four on five of them had reinfection with the same organism.
? Fifth patient was infected with a different organism
? Three of them had infection less than 1 month and next episode
cropped up between 1 – 6 months.
? Two patients died during readmissions.
? One patient is still in the premises and getting treated intensively.
? Etiology was not diagnosed in one and he succumbed to the
disease.
GRAPH 16: READMISSION
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MORTALITY:
? A very disappointing fact is that 9 out of 45 patients died.
? It   accounts  for  20% of  the  cases  admitted  with  fever,  which  is  a
striking fact that tells us the very importance of fever in renal
transplants
? All 9 of them were males.
? Two patients who had readmission died.
     Seven out of nine were between one to six months post transplant.
Two out of nine were in the category of more than 6 months post
transplant.
GRAPH 17: MORTALITY PATTERN
It is very important to review the site and organism that had been
implicated for mortality.
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SITE
SITE OF INFECTION DEATHS PERCENTAGE
RESPIRATORY TRACT 6 66.7%
CNS 1 11.1%
ISOLATION IN BLOOD
ALONE(WITH NO
OTHER FOCUS)
1 11.1%
UNDIAGNOSED 1 11.1%
TABLE 18: DEATH RATE WITH RESPECT TO SITE OF
INFECTION
Lung infections are the most common cause of death in the study
accounts for 66% of the deaths. The other 33% of deaths are shared as
mentioned in the table.
Lung involvement always had been too aggressive. It neither gave
time to the patient nor to the treating physician. It was very difficult site
to handle since many had hemoptysis and the alveoli were drowned in
their own blood hampering the respiratory exchange.
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INFECTIVE AGENT DISTRIBUTION:
The number of agents and the number of deaths will not match due
to polymicrobial infections.
INFECTIOUS AGENTS
RESPONSIBLE FOR DEATH
NUMBER OF
DEATHS PERCENTAGE
ASPERGILLUS 3 27.3%
POLYMICROBIAL 3 27.3%
MUCOR 1 9.1%
PNEUMOCOCCUS 1 9.1%
PSEUDOMONAS 1 9.1%
UNDIAGNOSED 2 18.1%
TABLE 19: DEATH RATE WITH RESPECT TO INFECTIVE
AGENT
GRAPH 18: DISTRIBUTION OF INFECTIOUS AGENT
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? All polymicrobial infections between 1 – 6 months died
? All aspergillus pneumonia ended up in the mortality list.
? Mucor, pneumococcus, pseudomonas were responsible for 1 death
each.
? There were two deaths, in which we failed to diagnose the etiology.
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SUMMARY OF RESULTS
? We have around 180 post transplant patients in routine follow up
with us in our Department of Nephrology.
? Forty five patients were admitted with fever during study period
? Seventy one percent of the patients were less than forty years and
twenty nine percent were more than forty years.
? Eighty four per cent of them were males and sixteen percent were
females.
? A high proportion of young and male population may be secondary
to the increasing in number of transplant correspondingly in that
subgroup.
? Only one patient’s native kidney disease was known in the whole
population
?  Seventy three percent of the population had live related donors and
twenty seven percent had cadaveric donors.
? Seven patients were treated for rejection and fifty seven percent of
them had respiratory infection.
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? Sixteen  patients had  their tacrolimus values higher than the
therapeutic range and fifty seven percent of them had respiratory
infections
? All of them were properly immunized and were compliant with
Pneumocystis prophylaxis.
? None of them had a significant environmental exposure or a pre-
existing disease.
? Fifteen percent of the patients have NODAT.
? Most of the patients presenting with fever, had no other clinical
signs and symptoms( forty nine percent)
? When investigated, twenty three percent had lung infections,
eighteen percent had urinary tract infection and twenty seven
percent remain undiagnosed
? Excluding culture and sensitivity (31.4%), CT chest (18%) was the
next productive tool of investigation.
? Early post-transplant infections (less than 1 month) are all hospital
acquired infections, contributing to four cases
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? In  the  above  category,  fifty  per  cent  of  them are  pneumonia.  UTI
and surgical site infection accounted for twenty five percent each.
? Intermediate post-transplant group (1 – 6 months) had diverse
etiology, with lung infections attributing to thirty five percent and
twenty six percent remain undiagnosed.
? In the above group, mucor and polymicrobial infection contributed
to thirteen percent each, whereas herpes, pneumococcus,
aspergillus contributed to nine percent each.
? Late post-transplant infections( more than 6 months), are involving
predominantly  urinary tract, gastro intestinal tract and respiratory
tract
? In the above category aspergillus, hepatitis c virus, undiagnosed are
the major problems accounting for 15% each, followed by
tuberculosis, herpes, e coli and polymicrobial infections accounting
for 10% each.
? Overall, five patients had mixed infections (nil in the early
transplant group, three in the intermediate group and two in the late
infections group).
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? All polymicrobial infections in the intermediate group succumbed
to infections and died.
? We had five readmissions and four of them had reinfection with the
same organisms, while one had infection with a different organism.
? There were nine deaths among the study group, which accounted
for 20%.
? All of them were males and five of them had high tacrolimus
levels.
? The predominant site of infection among the deceased is lung
(67%) and the predominant infections amongst them are aspergillus
and mixed infections (27% each).
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DISCUSSION
Fever in renal transplant recipients is interesting and invaluable as
it has a great say in the outcome of the patient. In general, infection in
patients with renal transplant are much less, when compared to other
organ transplants. The widely accepted reason is, renal transplant is an
elective or semi elective procedure, whereas the clinical and nutritional
status of the patient in other transplants is much worse32
We had a higher number of men in the study and in the mortality
list probably due to higher number of transplants among men. Other
demographic data did not yield much. This is similar to the Indian study
by Ram  et  al where the death is not influenced by age or sex32.  All  of
them were under immune suppression with prednisolone, tacrolimus, and
mycophenolate mofetil and were strictly adherent to pneumocystis
prophylaxis.
We had seven patients with NODAT and one in this category died.
Seven patients were treated for rejection and 57% of them had
involvement in the lungs. More than one third of the patients had high
tacrolimus levels and 57% had lung infections.
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A large percentage (49%), had clinically no other clue in the
history or examination for localizing the site or the organisms. Rest of the
population were diagnosed by diligent and systematic investigations.
After localizing the site of infection culture and sensitivity happened to
be the best tool and to localize the site, CT chest was the most productive
investigation.
Regarding the infections in the early transplant period, our results
are very similar to the results in the western literature and Indian studies
by Rubin  et  al and  the  study  from  CMC  Vellore  by George.T.John.
There are 4 cases which had fever. Out of the 4 cases two patients had
pneumonia, one had urinary tract infection and the last patient had
retroperitoneal abscess. The organisms that were involved were
Pseudomonas, Klebsiella, E.coli, and Enterobacter. All the organisms are
basically hospital derived pathogens and they are no different from a
normal person. All of them recovered from infections and survived the
scare. We had one recurrence from the 4 cases, which is the
retroperitoneal abscess. He is under treatment in the hospital for the same,
now. Despite immunosuppression and in concurrence with traditional
belief we never had any bizarre infection in this period. Urinary tract
infections are the most common cause of fever in the study by Ram et al,
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whereas pneumonia is the common organism in our study in this early
group.
In the intermediate transplant period, the most common infections
in our study were mucormycosis (13%) and polymicrobial infections
(13%). The next common infections following the above were aspergillus
and pneumococcus. Each of them contributed to 8.8% each. A majority of
the percentage (26%), in this group did not have a diagnosis and fell in
the undiagnosed category. Among the common sites, respiratory tract
contributes to the majority followed by skin. Rest of the system
mentioned previously more or less had equal involvement. Tuberculosis
was noted just over 4%.We had only one case of CMV compared to 21%
in Ram  et  al study  and  16%  of Shakuja et al33. One reason is,their
studies are based on infection where as ours is based on fever and many
CMV infected patients may have been diagnosed but not tabulated as
they were not febrile.
In the late transplant period, urinary tract infections, respiratory
tract infections and gastro intestinal infections are the common foci.
Aspergillosis, Hepatitis C viremia and the undiagnosed category
contributed to 45% and each contributing to 15%. Aspergillosis has
adverse occurrence with prevalence of just over 10% in Indian literature34
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and 0.7% in western literature35. Tuberculosis, Herpes, E.coli,
polymicrobial infection account for 10% each. Percentage of tuberculosis
varied between 3 to 13% in the Indian studies and in our study it is 4% in
the intermediate group and 10% in the late infection group.
EARLY
TRANSPLANT
PERIOD
INTERMEDIATE
TRANSPLANT
PERIOD*
LATE TRANSPLANT
PERIOD*
HOSPITAL ACQUIRED
? E COLI
? PSEUDOMONAS
? KLEBSIELLA
? ENTEROBACTER
? MUCOR
? POLYMICROBIAL
? PNEUMOCOCCUS
? ASPERGILLUS
? TUBERCULOSIS
? PSEUDOMONAS
? CRYPTOSPORIDIOSIS
? HCV
? ENTEROBACTER
? ASPERGILLUS
? HEPATITIS C
? TUBERCULOSIS
? HERPES
? POLYMICROBIAL
? E COLI
? KLEBSIELLA
? CMV
? BK VIRUS
TABLE 20: INFECTIONS DURING THE STUDY PERIOD IN
OUR STUDY: CLASSIFIED AND TABULATED
Another important area of interest is polymicrobial infection,
which in our study had significant impact on the patients. There were five
cases of polymicrobial infections, three in the intermediate group and two
in the late group. Well unfortunately, every patient with such infection in
the intermediate group died.
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A quick review of mortality yielded very important information.
Nine  out  of  the  45  patients  expired  in  the  study.  It  contributes  to  an
alarmingly  high  20%.   But  it  is  very  low  compared  to  the  studies  in
tropical countries with mortality rate between 20% - 60%12.  All  of  them
are males. The most common site of infection is lung contributing to
66%.  Most common organisms were Aspergillus and polymicrobial
infections contributing to 27% each. All patients with aspergillus
pneumonia (aspergillus involvement of other system not equally lethal in
our study) and as mentioned earlier all polymicrobial infection in the
intermediate group died.
We had 5 readmissions and four of them are admitted with
infection of same organism. Two of them died.
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Shortcomings of the study:
1. We had 3 attritions. They did not get followed up properly and were
essentially excluded from the study.
2.  Due to serious nature of the disease, few patients were started on
empirical antibiotics prior to culture. This could have suppressed
few of the organisms, which might have grown in the culture
otherwise.
3. Culture for few fastidious organisms could not be done due to
technical and financial constraints.
4.  Few were diagnosed with corroborative evidence and marked
improvement with treatment.
5. It under estimates the patients with infection because many infected
patients were afebrile and cannot be included in the study.
6. Study population and study period is small to be compared with
other national and international study.
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CONCLUSION
We had studied renal transplant recipient patients, who had fever
during the study period. We had patients who presented to us with
infections but without fever.  We never noticed any patient with non
infectious cause of fever (or few of the undiagnosed could have been a
non infectious cause). We had more men in the list and only men in the
mortality list, which may be due to the significant number of males who
underwent transplant. Other demographic data did not yield striking
notifications.  Most  of  them had live related donors and all  of  them were
immunized properly, compliant with pneumocystis prophylaxis and
immunosuppressed with prednisolone, tacrolimus, mycophenolate
mofetil. Among the patient treated with rejection 57% had respiratory
infections. One third of the patients had high tacrolimus values and 57%
patients with high tacrolimus values had respiratory tract infections.
Seven  patients  had  NODAT  in  this  study.  Majority  of  the  patients  with
fever had clinically no other clue to find the focus. Besides culture, CT
chest proved to be the single cost effective tool.
Early infections were nosocomial and is similar to any post-
operative patient. Among the intermediate group, common organisms
were mucor and polymicrobial infections and the common site was lung.
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In the late infections group urinary tract, respiratory tract, gastro intestinal
tract were commonly involved and Aspergillus and Hepatitis C viremia
were the common organisms.
Tuberculosis had a low incidence contrary to what we expected.
Only one case of Cytomegalovirus was reported and no pneumocystis
probably due to prophylaxis, in contrast to 15% in the study from NIMS32
Over all, a very satisfying experience to analyse the cause of fever
in  renal  transplant  recipients  and  to  chart  the  common  infections  that  is
existing in our locality. Hope we think about the common infections and
red flag information, which we analysed through the study, comes to our
mind every single time we treat them. (After all, their life means much
more to their family after transplant).
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PROFORMA
• NAME : SL. NO:
• AGE /SEX:
HISTORY
1. DONOR:
NATURE OF DONOR : (LIVE RELATED/DECEASED)
ANY KNOWN DISEASE/ COMORBIDITY IN THE
PAST/EXISTING:
EPIDEMIOLOGICAL FACTORS/ EXPOSURE PRIOR TO
TRANSPLANT:
2. RECIPIENT:
NATIVE KIDNEY DISEASE:
NATURE OF IMMUNOSUPPRESSION:
(RECEIVED INDUCTION: YES/NO)
TREATMENT FOR REJECTION, IF ANY:
POST OPERATIVE COMPLICATIONS, IF ANY:
APPROPRIATE VACCINATION:
COMPLIANCE ON PCP PROPHYLAXIS:
PRESENCE OF NODAT ( New Onset Diabetes After Transplant):
            LEVEL OF TACROLMUS
 TIMING OF FEVER SINCE TRANSPLANT:
< 1 MONTH
1- 6 MONTHS
> 6 MONTHS
PATIENT’S FEVER DESCRIPTION:
               SIMILAR ILLNESSES/ SIGNIFICANT ILNESSES IN BOTH
PRE & POST TRANSPLANT PERIODS:
3. RELEVANT HISTORIES AS APPROPRIATE AS THE
PATIENT’S SCENARIO DEMANDS
 RELEVANT CLINICAL EXAMINATION:
INVESTIGATIONS (TAILORED FOR EACH CASE):
FINAL DIAGNOSIS:
FOLLOW UP (IF APPLICABLE):
MASTER CHART
 S NO NAME AGE SEX
PRE
EXIST
DISEASE
EPI
EXPOSUR
E
NKD NATURE OFDONOR
NATURE OF
IMMUNOSUPPRESION
TREATMENT
OF
REJECTION
VACCIN
ATION
PCP
PROPHYLAXIS
COMPLIANCE
LEVEL OF
TACROLIMUS NODAT
TIMING OF
FEVER POST
TRANSPLAN
T
PAST
ILLNESS RELEVANT CLINICAL DATA CLINCHING INVESTIGATIONS FINAL  DIAGNOSIS
FOLLOW
UP
1 nazer ali 27 m nil nil nk C TI yes yes compliant HIGH yes >6 months nil no other clues granuloma in bm biopsy tuberculosis fine
2 john 20 m nil nil nk L TI no yes compliant IN RANGE yes >6 months nil no other clues none undiagnosed fine
3 giri 23 m nil nil nk L TI no yes compliant IN RANGE no >6 months nil abscess in ring finger pcr for tb + tuberculosis fine
4 alli 45 f nil nil nk C TI no yes compliant IN RANGE no 1-6 months nil vesicles in dermatomaldistribution tzanck smear herpes zoster fine
5 shankar 53 m nil nil nk L TI no yes compliant IN RANGE no 1-6 months nil swelling L wrist granuloma in synovial biopsy tuberculosis fine
6 kesavan 37 m nil nil nk L TI no yes compliant IN RANGE no >6months nil no other clues anti hcv and rna + hepatitis fine
7 amthul nali 29 f nil nil nk C TI no yes compliant IN RANGE no >6months nil no other clues pp 65 positive cmv fine
8 srinivasan 14 m nil nil nk L TI no yes compliant IN RANGE no 1-6 months nil cough;otherwise normal ct chest and sputum culture -pneumococcus
pneumococcal
pneumonia fine
9 santhana kumar 14 m nil nil nk C TI no yes compliant IN RANGE no >6months nil no other clues nil undiagnosed fine
10 suresh 37 m nil nil nk L TI no yes compliant HIGH no >6months nil cough ct chest  shows patch and sputumculture -ve
pneumonia and
agent not known fine
11 Raghu 40 m nil nil nk L TI no yes compliant IN RANGE no >6months nil headache csf- polymorphs acute cns infection death
12 karuppusamy 30 m nil nil nk L TI no yes compliant IN RANGE no 1-6 months nil nil nil undiagnosed fine
13 dhanalaxmi 23 f nil nil nk L TI no yes compliant IN RANGE no >6months nil ear discharge urine c/s-klebsiella;ear discharge c/s-aspergillosis uti and csom fine
14 selvam 43 m nil nil nk L TI no yes compliant HIGH yes 1-6 months nil nil nil undiagnosed fine
15 murugan 40 m nil nil nk L TI no yes compliant IN RANGE no 1- 6 months nil nil smear for mp - +ve malaria fine
16 jayaprakash 28 m nil nil nk L TI no yes compliant IN RANGE yes >6months nil vesicles in dermatomaldistribution tzanck smear + ve herpes zoster fine
17 srinivasan 14 m nil nil nk L TI no yes compliant HIGH no <1 month nil post op blood c/s- pseudomonas pseudomanal-septicemia fine
18 somasundaram 22 m nil nil nk L TI no yes compliant IN RANGE no 1-6 months nil vesicles tzanck smear-+ve varicella zoster fine
19 shanmuga perumal 18 m nil nil nk L TI no yes compliant IN RANGE no <1 month nil nil urine c/s - e coli uti fine
20 devi 31 f nil nil nk L TI no yes compliant IN RANGE no >6 months recurrentuti nil urine c/s - e coli uti fine
21 mohammed rafi 24 m nil nil nk L TI no yes compliant IN RANGE no >6 months nil cough ct - pns- ?fungal ball; biopsy -aspergillosis fungal sinusitis fine
22 venkatesan 39 m nil nil nk L TI no yes compliant IN RANGE no 1-6 months nil nil smear for mp - +ve malaria fine
23 poonkodi 45 f nil nil nk L TI no yes compliant IN RANGE no >6 months nil vesicles in dermatomaldistribution tzanck smear-+ve herpes zoster fine
24 ramesh 25 m nil nil nk C TI no yes compliant IN RANGE yes >6 months nil icterus hcv rna significantly  high acute hepatitis hcvrelated fine
25 manjunathan 22 m nil nil nk L TI yes yes compliant IN RANGE no >6 months nil nil hcv rna significantly  high hepatitis hcv related fine
26 ranjith kumar 26 m nil nil nk C TI yes yes compliant HIGH no <1 month nil crepitation over lung fields ct chest- b/l pneumonia;culture -klebsiella
nosocomial
peumonia fine
27 devaki 23 f nil nil nk C TI no yes compliant IN RANGE yes >6 months nil nil nil undiagnosed fine
28 kumaresan 28 m nil nil nk L TI no yes compliant IN RANGE no >6 months recurrentuti nil uti;c/s- ecoli; decoy cells-
uti;e coli; bk virus
infection fine
29 antony 25 m nil nil nk L TI no yes compliant IN RANGE no 1-6 months nil fever;diarrhoea nil undiagnosed fine
30 jeyaraj 35 m nil nil nk L TI no yes compliant IN RANGE no 1-6 months nil nil nil undiagnosed fine
31 munuswamy 35 m nil nil nk L TI no yes compliant HIGH no 1-6 months nil nil febrile neutropenia;consolidation in ctchest
pnemococcus
pneumonia and
sepsis
death
32 suresh 39 m nil nil nk L TI no yes compliant IN RANGE no 1-6 months nil nil polymicrobial sepsis in blood culture polymicrobial sepsis death
33 ranjith kumar 23 m nil nil nk L TI yes yes compliant HIGH no 1-6 monthspost op pneumonia cough
ct chest  left lung
abscess;pseudomonas and
aspergillosis
lung abscess with
sepsis death
34 jerry bosco 48 m nil nil nk L TI yes yes compliant HIGH no 1-6 months nil nil pneumonia in ct chest;sputum c/s-poly microbial
pneumonia with
sepsis death
35 govindaraj 43 m nil nil antigbm L TI no yes compliant IN RANGE no 1-6 months nil nil
pneumonia in ct chest;sputum c/s-
mucor
pneumonia with
sepsis death
36 prabhu 35 m nil nil nk L TI no yes compliant HIGH no 1-6 months nil cavernous breath sounds; cavitating pneumonia;sputum-aspergillosis
pneumonia with
sepsis death
37 arasu 40 m nil nil nk C TI no yes compliant HIGH no 1-6 months nil fever;diarrhoea nil undiagnosed death
38 poongodi 40 f nil nil nk C TI no yes compliant IN RANGE no 1-6 months nil icterus hcv rna significantly  high hcv related hepatitis fine
39 saravanan 39 m nil nil nk L TI yes yes compliant HIGH yes >6 months nil cough   ct chest- pneumonia;c/s-aspergillosis
aspergillosis
pneumonitis death
40 kandaswamy 45 m nil nil nk C TI no yes compliant HIGH no 1-6 months nil nil ct-chest-patch;FNAC-mucor mucormycosis fine
41 kandaswamy 45 m nil nil nk C TI no yes compliant HIGH no >6 months nil nil ct-chest-patch;FNAC-mucor mucormycosis In hospital
42 gopalakrishnan 26 m nil nil nk L TI no yes compliant HIGH no <1 month nil abdominal pain; ct abdomen pus collection;aspirationand culture-enterobacter
retroperitoneal
abscess;
enterobacter
fine
43 gopalakrishnan 26 m nil nil nk L TI no yes compliant HIGH no 1-6 months
retroperiton
eal
abscess
abdominal pain; ct abdomen pus collection;aspirationand culture-enterobacter
retroperitoneal
abscess;enterobacter
;recurrence
fine
44 arasu 40 m nil nil nk C TI no yes compliant HIGH no 1-6 months nil fever;diarrhoea nil undiagnosed death
45 chinna ettu 25 m nil nil nk L TI yes yes compliant IN RANGE no 1-6 months nil diarrhoea stool microscopy and acid fast-cryptosporidiosis cryptosporidiosis fine
KEY FOR MASTER CHART
M Male
F Female
NKD Native Kidney Disease
NK Not Known
L Live Related
C Cadaver
TI Triple immunosuppression with prednisolone, tacrolimus,
mycophenolate mofetil
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